✨ Miscellaneous Notices




NEW ZEALAND GAZETTE, No. 22 β€” 2 MARCH 2017

Companies on 8 July 2016 with the rights to surplus funds arising from a mortgagee sale.
Dated at Wellington this 23rd day of February 2017.

WILLIAM HENRY DAVID MORE, Senior Solicitor.

2017-go908


Lynton Downs School (3422) Closure Notice

Pursuant to section 154 of the Education Act 1989, I hereby declare that Lynton Downs School (3422), Kaikoura District, will close on 28 April 2017 and will cease to be established on that day.
Dated at Wellington this 22nd day of February 2017.

KATRINA CASEY, Deputy Secretary, Sector Enablement and Support, Ministry of Education.

2017-go910


Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981 ("Act"), the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:

Schedule

Product:
Arcoxia

Active Ingredient:
Etoricoxib 30mg

Dosage Form:
Film coated tablet

New Zealand Sponsor:
Merck Sharp & Dohme (New Zealand) Limited

Manufacturers:
Frosst Iberica SA, Madrid, Spain
Merck Sharp & Dohme Corp, Virginia, United States of America

Product:
Arcoxia

Active Ingredient:
Etoricoxib 60mg

Dosage Form:
Film coated tablet

New Zealand Sponsor:
Merck Sharp & Dohme (New Zealand) Limited

Manufacturers:
Frosst Iberica SA, Madrid, Spain
Merck Sharp & Dohme Corp, Virginia, United States of America

Product:
Arcoxia

Active Ingredient:
Etoricoxib 90mg

Dosage Form:
Film coated tablet

New Zealand Sponsor:
Merck Sharp & Dohme (New Zealand) Limited

Manufacturers:
Frosst Iberica SA, Madrid, Spain
Merck Sharp & Dohme Corp, Virginia, United States of America

Product:
Arcoxia

Active Ingredient:
Etoricoxib 120mg

Dosage Form:
Film coated tablet

New Zealand Sponsor:
Merck Sharp & Dohme (New Zealand) Limited

Manufacturers:
Frosst Iberica SA, Madrid, Spain
Merck Sharp & Dohme Corp, Virginia, United States of America

Product:
Perjeta

Active Ingredient:
Pertuzumab 420mg equivalent to 30mg/mL

Dosage Form:
Concentrate for infusion

New Zealand Sponsor:
Roche Products (NZ) Limited

Manufacturer:
Roche Diagnostics GmbH, Mannheim, Germany

Dated this 24th day of February 2017.

CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).

2017-go938

53



Next Page →



Online Sources for this page:

Gazette.govt.nz PDF NZ Gazette 2017, No 22





✨ LLM interpretation of page content

πŸ’° Notice of Vesting of Property Under Section 324 of the Companies Act 1993β€”Authentic Straw Bale Construction Limited

πŸ’° Finance & Revenue
23 February 2017
Companies Act 1993, Vesting of Property, Mortgagee Sale, Surplus Funds, Crown
  • William Henry David More, Senior Solicitor

πŸŽ“ Lynton Downs School (3422) Closure Notice

πŸŽ“ Education, Culture & Science
22 February 2017
School Closure, Education Act 1989, Kaikoura District
  • Katrina Casey, Deputy Secretary, Sector Enablement and Support, Ministry of Education

πŸ₯ Consent to the Distribution of New Medicines

πŸ₯ Health & Social Welfare
24 February 2017
Medicines Act 1981, New Medicines, Distribution Consent, Arcoxia, Perjeta
  • Chris James, Group Manager, Medsafe, Ministry of Health